211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

Publication | Open Access

DOI Full Paper Access

Citations

References

2022

Year

M. Martín Jiménez, Elgene Lim, Mariana Chávez‐MacGregor, Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, F. Melo Cruz, S-B. Kim, Christian Schem,

Annals of Oncology

Endocrine OncologyVs Physician ChoiceAdvanced/metastatic Breast CancerPhase IiBreast OncologyMedicineClinical TrialsGynecologyBreast CancerPharmacotherapyOncologyRadiation OncologyEndocrine-related CancerHealth Sciences